港股详情

本页面由TTMF Limited提供服务

华芢生物-B待上市

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：1.18亿

香港流通股本：8,302.21万

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

1

开始申购

12/12

2

申购截止

12/17 09:30

3

公布中签

12/18

4

暗盘

12/19 16:15 - 18:30

5

挂牌上市

12/22

总览公司新闻资讯公告

公司资料

公司名字：

华芢生物-B

交易所：

SEHK

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.huarenshengwu.com

邮编：

- -

电话：

- -

传真：

- -

简介：

我们成立于2012年,是一家总部位于中国的生物制药公司,致力于开发疗法,重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。我们的主攻方向是发现、开发和商业化伤口愈合的疗法,目前为PDGF药物。截至最后实际可行日期,我们的管线包含十款候选产品,其中七款为PDGF候选药物,包括两款核心产品,即用于治疗烧烫伤的Pro-101-1及用于治疗糖足的Pro-101-2,是rhPDGF-BB药物。

董事

名称

职位

贾丽加

董事会主席，执行董事，薪酬委员会委员，提名委员会委员，内部控制委员会主席

王轲珑

董事会副主席，执行董事

翟俊辉

执行董事

苗天祥

执行董事

霍志达

独立非执行董事，内部控制委员会委员，审核委员会委员

李嘉焱

独立非执行董事，薪酬委员会委员，提名委员会委员，内部控制委员会委员，审核委员会委员

岳仪春

独立非执行董事，薪酬委员会主席，提名委员会主席，内部控制委员会委员，审核委员会主席

林颖

非执行董事

袁飞

非执行董事

宋冰

监事会主席，监事

刘亚利

监事

陈炫宇

监事

股东

名称

职位

王轲珑

总裁

翟俊辉

总经理

何鸿添

副总裁，首席财务官，董事会秘书，联席公司秘书

徐震宇

副总裁，首席营销官

黄慧儿

联席公司秘书

成龙

医学总监

苗天祥

首席战略官

赵兴卉

首席研发官

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02396/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02396","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02396\",,,,,undefined,":{"symbol":"02396","market":"HK","secType":"STK","nameCN":"华芢生物-B","latestPrice":0,"timestamp":1765785600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":83022145,"shares":117657522,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-15 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":8,"adr":0,"listingDate":1766332800000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0,"ipoDetail":{"name":"华芢生物－Ｂ","exchange":"SEHK","listingDate":"2025-12-22","sharesOutstanding":117657522,"sharesFloat":117657522,"offerAmount":17648800,"priceRange":"38.200 - 51.000","market":"HK","openProspectusDate":"2025-12-12","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1212/2025121200082_c.pdf","purchaseBeginDate":"2025-12-12","purchaseEndDate":"2025-12-17","winningDate":"2025-12-19","currency":"HKD","minPurchaseQuantity":200,"peRate":-23.18,"use":"1、约61.8%或437.6百万港元，将用于资助公司核心产品Pro101-1及Pro-101-2的持续临床开发及商业化；\n2、约18.8%或133.5百万港元，将用于通过购买与研发及质量控制活动相关的专业设备及仪器来提升公司研发能力；\n3、约6.3%或44.5百万港元，将用于支付公司核心产品以外的PDGF产品用于治疗其他适应症的持续临床前研发的第三方服务费、研发人员费用及原材料成本；\n4、约3.1%或22.3百万港元，将用于支付Mes-201、Oli-101及Oli201临床前研发活动的第三方服务费、研发人员费用及原材料成本；\n5、约10.0%或70.9百万港元，用作营运资金及一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家总部位于中国的生物制药公司，致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物，主攻方向是发现、开发和商业化伤口愈合的疗法，目前为PDGF药物。","subscribed":127.75,"marketCap":4495000000,"minimumCapital":10302.88,"overAllotment":true,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,450000,500000,600000,700000,882400"},"greyMarketDetail":{"greyDate":"2025-12-19","greyDateTimestamp":1766073600000,"greyOpeningTime":1766132100000,"greyClosingTime":1766140200000,"showGreyQuote":false,"openProspectusDate":"2025-12-12","listingDate":"2025-12-22"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02396\",,,,,undefined,":{"symbol":"02396","floatShares":83022145,"roa":"--","roe":"--","lyrEps":0,"shares":117657522,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02396\",,undefined,":{"id":9245,"type":"COMMON","ipoName":"02396-IPO","symbol":"02396","companyName":"华芢生物-B","market":"HK","currency":"HKD","status":"OPEN","underwriter":"华泰金融控股(香港)有限公司","lotSize":200,"minQty":200,"expectedOfferingSize":17648800,"openingDate":1765503000000,"closingDate":1765935000000,"commonClosingDate":1765935000000,"allotmentDate":1765987200000,"listDate":1766332800000,"marginable":true,"marginRate":10,"latestPrice":51,"minPrice":38.2,"maxPrice":51,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1212/2025121200082_c.pdf","allowedQuantities":[200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,450000,500000,600000,700000,882400],"interestRate":0,"recommend":false,"isHint":false,"interestStartDate":1765900800000,"interestEndDate":1765900800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1766132100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[{"ipoName":"02396-IPO","financingId":55872,"type":1,"availableFundLimit":10302.86,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":103028.6,"maxSubscribeLimit":-1,"marginRate":10,"interestRate":0,"openTime":1765503000000,"closeTime":1765935000000,"isAtValidTime":true,"subscriptionMethod":"FINANCING","processFee":0,"supportPI":false,"applyFundLimit":10302.86,"threshold":8000000000,"isAvailable":false},{"ipoName":"02396-IPO","financingId":55865,"type":4,"availableFundLimit":10302.86,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":0,"maxSubscribeLimit":-1,"marginRate":100,"interestRate":0,"openTime":1765503000000,"closeTime":1765935000000,"isAtValidTime":true,"subscriptionMethod":"CASH","processFee":0,"supportPI":false,"applyFundLimit":10302.86,"threshold":10000000000,"isAvailable":false}],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[{"method":"CASH","closeTime":1765935000000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":10302.86},{"method":"FINANCING","closeTime":1765935000000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":10302.86}],"latestClosingDate":1765935000000,"subscribedFinanceRatio":127.75,"subscribedRatio":127.75,"forecastRatio":148.19,"raiseMoney":90020000,"totalMargin":11499520000,"quoteInfoUpdatedAt":1765787842334,"forecastMarketValue":5247525481.2,"minForecastMarketValue":4494517340.400001,"maxForecastMarketValue":6000533622,"sharesOutstanding":117657522,"business":"公司是一家总部位于中国的生物制药公司，致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物，主攻方向是发现、开发和商业化伤口愈合的疗法，目前为PDGF药物。","greyOpeningTime":1766132100000,"greyClosingTime":1766140200000,"tradable":true},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.huarenshengwu.com","compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"我们成立于2012年,是一家总部位于中国的生物制药公司,致力于开发疗法,重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。我们的主攻方向是发现、开发和商业化伤口愈合的疗法,目前为PDGF药物。截至最后实际可行日期,我们的管线包含十款候选产品,其中七款为PDGF候选药物,包括两款核心产品,即用于治疗烧烫伤的Pro-101-1及用于治疗糖足的Pro-101-2,是rhPDGF-BB药物。","exchange":"SEHK","name":"华芢生物-B","nameEN":"B&K CORP-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02396\",market:\"HK\",,,undefined,":{"directors":[{"name":"贾丽加","position":"董事会主席，执行董事，薪酬委员会委员，提名委员会委员，内部控制委员会主席"},{"name":"王轲珑","position":"董事会副主席，执行董事"},{"name":"翟俊辉","position":"执行董事"},{"name":"苗天祥","position":"执行董事"},{"name":"霍志达","position":"独立非执行董事，内部控制委员会委员，审核委员会委员"},{"name":"李嘉焱","position":"独立非执行董事，薪酬委员会委员，提名委员会委员，内部控制委员会委员，审核委员会委员"},{"name":"岳仪春","position":"独立非执行董事，薪酬委员会主席，提名委员会主席，内部控制委员会委员，审核委员会主席"},{"name":"林颖","position":"非执行董事"},{"name":"袁飞","position":"非执行董事"},{"name":"宋冰","position":"监事会主席，监事"},{"name":"刘亚利","position":"监事"},{"name":"陈炫宇","position":"监事"}],"executives":[{"name":"王轲珑","position":"总裁"},{"name":"翟俊辉","position":"总经理"},{"name":"何鸿添","position":"副总裁，首席财务官，董事会秘书，联席公司秘书"},{"name":"徐震宇","position":"副总裁，首席营销官"},{"name":"黄慧儿","position":"联席公司秘书"},{"name":"成龙","position":"医学总监"},{"name":"苗天祥","position":"首席战略官"},{"name":"赵兴卉","position":"首席研发官"}]}}}